Latest news with #Austedo
Yahoo
01-08-2025
- Business
- Yahoo
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the Zacks Consensus Estimate of 63 cents. Adjusted earnings rose 8% year over year, driven by higher operating profits. Revenues for the second quarter were $4.18 billion, which missed the Zacks Consensus Estimate of $4.28 billion. Total revenues were flat year over year on a reported basis and down 1% on a constant currency basis. Revenue growth suffered as the gains from the increasing sales of its branded drugs, Austedo, Ajovy, and Uzedy, were offset by lower generic drug sales in Teva's U.S. and international markets, mainly resulting from its exit from Japan. Branded Products Drive TEVA's US Unit's Sales Sales in the United States segment were $2.15 billion, up 2% year over year, driven by higher revenues from Teva's branded drugs, Ajovy, Austedo and Uzedy, partially offset by a decline in generic revenues. The segment's sales missed the Zacks Consensus Estimate of $2.19 billion but beat our model estimate of $2.11 billion. Generic/biosimilar product revenues declined 6% from the year-ago period to $961 million in the United States due to lower revenues from the generic versions of Revlimid and Victoza. Generic revenues missed the Zacks Consensus Estimate of $1.05 billion as well as our model estimate of $1.02 billion. Teva's ne generic drugs includes Simlandi, a generic version of AbbVie's ABBV Humira, which was approved in February 2024 and launched in May. Teva also has other high-value complex generics like Selarsdi. Notably, Selarsdi is a biosimilar version of J&J's JNJ Stelara, which was approved in April 2024 and launched in February 2025, per settlement terms with J&J. Simlandi and Selarsdi are the first two biosimilars to launch in the United States under the Teva and Alvotech strategic partnership, which includes nine products. Teva and partner Samsung Bioepis' Epysqli, a biosimilar version of AstraZeneca's Soliris, was launched in the United States in early April. Teva entered into a strategic partnership with Samsung Bioepis in January 2025 for the commercialization of Epysqli in the United States. So far this year, shares of TEVA have plunged 23.6% compared with the industry's decline of 9.8%. Image Source: Zacks Investment Research Huntington's disease drug, Austedo, recorded sales of $495 million in the United States, up 22% year over year. Sales were mainly driven by volume growth as prescription trends continued to grow. Austedo sales missed the Zacks Consensus Estimate of $501.7 million while marginally beating our model estimate of $494.8 million. Ajovy recorded sales of $63 million in the quarter, up 53% year over year, driven by volume growth. Ajovy sales surpassed the Zacks Consensus Estimate of $50.8 million as well as our model estimate of $42.6 million. Uzedy (risperidone), a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia, generated sales of $54 million in the second quarter, up 120% year over year, mainly driven by volume growth. Copaxone recorded sales of $62 million in the United States, down 23% year over year, mainly due to market share erosion and competition. Copaxone sales beat the Zacks Consensus Estimate of $48.8 million as well as our model estimate of $45.8 million. Performance of TEVA's Europe and International Market Units The Europe segment recorded revenues of $1.3 billion, up 7% year over year on a reported basis. Sales were up 3% on a constant currency basis, mainly driven by the sale of certain product rights, higher revenues from Ajovy and generic products. Europe revenues beat the Zacks Consensus Estimate as well as our model estimate of $1.25 billion. In the International Markets segment, sales declined 17% year over year to $495 million. In constant currency terms, sales decreased 16% year over year, mainly due to the divestment of Teva's business venture in Japan. International Markets revenues missed the Zacks Consensus Estimate of $602.4 million as well as our model estimate of $651.3 million. The Other segment (comprising the sales of active pharmaceutical ingredients to third parties and certain contract manufacturing services) recorded revenues of $232 million, down 7% year over year on a reported basis and down 9% year over year on a constant currency basis. TEVA's Margin Discussion Adjusted gross margin was 54.6% for the quarter, up 170 basis points (bps) year over year. The rise is mainly driven by higher Austedo revenues, the sale of certain product rights in Europe and the divestment of the business venture in Japan, partially offset by lower Copaxone revenues. Adjusted research & development expenses decreased 9% year over year to $244 million. Selling and marketing expenditure was comparatively flat year over year at $654 million. General and administrative expenses increased 8% from the prior-year level to $305 million. Adjusted operating income rose 7% year over year in the second quarter to $1.13 billion. Adjusted operating margin increased 180 bps to 27.1% in the quarter, mainly due to higher gross profit margin as well as lower operating expenses as a percentage of revenues. Teva expects an adjusted operating margin of 30% by 2027 to be achieved by cost savings and the continued growth of its branded drugs. Teva Pharmaceutical Industries Ltd. Price, Consensus and EPS Surprise Teva Pharmaceutical Industries Ltd. price-consensus-eps-surprise-chart | Teva Pharmaceutical Industries Ltd. Quote TEVA Updates Guidance for 2025 Teva continues to expect its total revenues in 2025 to be in the range of $16.8-$17.2 billion. Teva raised the lower end of its expectation for Austedo from $1.95-$2.05 billion to $2-$2.05 billion. The company also raised its full-year guidance for Ajovy sales from $600 million to the range of $630-$640 million. Uzedy guidance has been raised from $160 million to the range of $190-$200 million in 2025. Copaxone guidance was maintained at $370 million. Teva expects adjusted EPS to be in the range of $2.5-$2.65 per share in 2025 compared with the prior expectation of $2.45-$2.65. The company continues to expect its adjusted operating income to be in the range of $4.3-$4.6 billion in 2025. Adjusted EBITDA was maintained in the range of $4.7-$5 billion. TEVA's Zacks Rank Teva currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Reuters
30-07-2025
- Business
- Reuters
Teva Pharm's second-quarter profit boosted by branded drugs, US tariff questions remain
JERUSALEM, July 30 (Reuters) - Teva Pharmaceutical Industries ( opens new tab reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26% rise in sales of its branded drugs and said it was well positioned to mitigate potential U.S. tariffs. Richard Francis, CEO of Teva, the world's largest generic drugmaker, said there was "big ambiguity" and "so many unanswered questions" in the pharmaceuticals sector regarding potential U.S. import levies. He added, however, that the Israel-based company, had been leveraging its U.S.-based manufacturing facilities and its minimal reliance upon China and India to soften the blow from any eventual tariffs. "Those aspects just set us up in the face of this change, probably a lot better than our competitors," Francis told Reuters. "I feel we have the ability to put ourselves in a good position here, with the caveat - I need to know the details." U.S. President Donald Trump initially threatened Israel with a 17% import tariff on its exports to the United States. But what will happen after his August 1 deadline expires remains unclear. Global drugmakers also face the possibility of a sector-specific U.S. tariff on pharmaceuticals despite some drug shortages in the United States. Teva said it earned 66 cents per diluted share, excluding one-time items, in the April-June quarter, up from 61 cents a share a year earlier. Revenue was flat in dollar terms at $4.18 billion. Analysts had forecast earnings of 62 cents per share ex-items for the Israel-based company on revenue of $4.28 billion, LSEG I/B/E/S data showed. Teva largely reaffirmed its 2025 estimates but revised its adjusted EPS forecast to $2.50-$2.65 from $2.45-$2.65. It still projects revenue of $16.8 billion to $17.2 billion this year and said it was on track for 30% operating profit margin by 2027. After a strong 2024, generic drugs were largely flat globally in the quarter, falling in the United States but offset by gains in Europe. Among its branded drugs, sales of its Huntington's Disease treatment Austedo grew 19% to $498 million, while migraine medicine Ajovy rose 31% to $155 million and Uzedy, a drug to treat schizophrenia, jumped 120% to $54 million. As a result, Teva raised its estimate for 2025 sales of Austedo slightly to $2 billion to $2.05 billion. It sees sales of Ajovy at $630 million to $640 million and Uzedy at $190 million to $200 million. It added it would double biosimilar revenues from 2024 to 2027 and said it remained in negotiations to sell its active pharmaceutical ingredients unit. Teva, Francis noted, has a large pipeline of drugs that will be launched in the coming decade - starting with schizophrenia drug Olanzapine in the fourth quarter - that combined will likely peak at more than $10 billion in sales. Its New York-listed shares were up 2.9% at $17.15 in mid-morning trade.
Yahoo
30-07-2025
- Business
- Yahoo
Teva Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. The company reported total revenue of $4.20 billion, falling short of analysts' expectations of $4.29 billion, according to Benzinga Pro. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms. The revenue shortfall was primarily driven by weaker sales in Teva's generic drug portfolio. Specifically, the decline in generic revenues from its International Markets segment, compounded by the divestment of its Japanese business and a drop in sales from Copaxone, weighed on overall these declines were partially offset by strong sales growth from Teva's innovative drug offerings, including Austedo, Uzedy, and Ajovy. Sales of Copaxone, a key multiple sclerosis treatment, fell by 23%, contributing just $62 million in revenue for the quarter. On a more positive note, Teva's innovative portfolio saw impressive growth. Austedo, an FDA-approved treatment for tardive dyskinesia, saw a 19% increase in sales, reaching $498 million. Uzedy, used in the treatment of schizophrenia, more than doubled its sales, totaling $54 million. Similarly, Ajovy, a migraine treatment, reported a 31% year-over-year increase, bringing in $155 million. Teva's generic segment showed stable performance overall. Global generics revenues declined by 2% in local currency, excluding Japan's business venture, while U.S. generics saw a 6% drop. In contrast, European generics grew by 1%, and revenues from the International Markets segment fell by 1%. Teva also reported strong growth in its biosimilars segment. The company attributed this to the robust performance of both existing and newly launched biosimilars. Teva expects this segment to continue growing, with plans to launch two new biosimilars in the second half of 2025. The company is on track to double biosimilars revenues from 2024 to 2027, underscoring its commitment to expanding its portfolio in this rapidly growing sector. For the second quarter, Teva reported adjusted earnings of 66 cents per share, surpassing analyst estimates of 62 cents per share. The adjusted gross profit margin for the quarter improved to 54.6%, compared to 52.9% in the same period last year, reflecting the favorable mix of higher-margin innovative products. Teva's President and CEO, Richard Francis, highlighted the company's growing portfolio as a key driver of its financial performance. 'Teva's performance this quarter stands as a testament to the exceptional strength of our innovative portfolio, which remains the primary engine driving our revenue growth,' Francis said. 'Our key innovative products delivered a 26% increase in local currency, demonstrating their impact on our financial trajectory and value to patients.' View more earnings on TEVA During the earnings conference call, Francis stated that 70% of Teva's generics business operates outside the U.S., while its most innovative business is U.S.-based. On the supply chain, Teva has no reliance on China and a very small presence in India. Teva's CFO Eli Kalif confirmed that U.S. tariffs are absorbed into their 2025 non-GAAP outlook, indicating proactive financial planning to manage these impacts. Outlook Teva Pharmaceutical narrowed its fiscal 2025 adjusted earnings guidance to a range of $2.50-$2.60 per share from $2.45-$2.65 per share, slightly below the consensus estimate of $2.53. The company also reaffirmed its full-year sales guidance of $16.8 billion-$17.2 billion, slightly lower than the consensus expectation of $17.01 billion. This outlook takes into account the potential impact of tariffs and trade uncertainties within the pharmaceutical sector. Teva raised its sales outlook for several key products. The sales forecast for Austedo in 2025 was increased to between $2 billion and $2.05 billion, up from the prior estimate of $1.95-$2.05 billion. Similarly, the company now expects Ajovy sales to reach $630 million-$640 million, surpassing its earlier guidance of $600 million. Sales expectations for Uzedy were also raised from approximately $160 million to a range of $190-$200 million. Teva also expects around $370 million in sales from Copaxone in 2025. For its operating income and adjusted EBITDA, Teva reaffirmed its guidance range of $4.3 billion-$4.6 billion and $4.7 billion-$5 billion, respectively. The company remains focused on executing its long-term strategy, which includes building a $5 billion innovative medicines franchise by 2030, supported by its key assets and promising late-stage pipeline. As the company continues its pivot toward innovative therapies, it remains to be seen how it will navigate potential headwinds, including tariff impacts and competition in both its generic and biosimilar segments. Price Action: TEVA stock is trading higher by 2.36% to $16.94 at last check Wednesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? TEVA PHARMACEUTICAL INDUS (TEVA): Free Stock Analysis Report This article Teva Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
11-07-2025
- Business
- Yahoo
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited's TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics, with many more in the pipeline. The company's newer branded drugs, such as Austedo, Uzedy and Ajovy, are experiencing strong sales growth. Teva has implemented cost-cutting measures to improve its operating profits while reducing debt burden. All these factors have played a key role in the stock's price appreciation in the past three months. Let's discuss these factors in detail to understand how to play TEVA stock at present. The company is seeing continued market share growth of its two newest branded drugs, Austedo and Ajovy. Though Teva is seeing slightly slower growth of Ajovy in the U.S. market, it expects sales to benefit from continued patient growth and launches in additional countries in Europe and international markets. For Austedo, Teva expects to achieve annual revenues of more than $2.5 billion by 2027. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects to launch Austedo in European markets in 2026. Uzedy (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia in adults, was launched in May 2023 in the United States. In 2025, Uzedy sales are expected to be approximately $160 million. The company has also made decent progress with its branded pipeline, which includes olanzapine, a long-acting subcutaneous injectable (LAI) for treating schizophrenia and duvakitug, its anti-TL1A therapy for inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD). Teva has partnered with Sanofi SNY for duvakitug to maximize the value of the asset. Teva and Sanofi will equally share the development costs globally. Teva's partner, Sanofi, plans to advance duvakitug, into phase III trials for both UC and CD in the fourth quarter of 2025. The company expects to file a new drug application to seek approval for olanzapine in the second half. Teva anticipates generating more than $5 billion in revenues from its branded products by 2030. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value complex generics, including Novo Nordisk's Victoza, Roche's cancer drugs Rituxan (Truxima) and Herceptin (Herzuma), AbbVie's Humira (Simlandi), J&J's JNJ Stelara (Selarsdi), Novartis' Sandostatin LAR and AstraZeneca's Soliris (Epysqli). Teva has a decent pipeline of biosimilars, with some being developed in partnership with Alvotech, including high-value complex generics like Simlandi and Selarsdi. These are the first two biosimilars to be launched in the United States under the Teva and Alvotech strategic partnership, which includes five biosimilars. TEVA expects to launch seven (including Simlandi and Selarsdi) biosimilars in the United States and four in Europe between 2025 and 2027. Biosimilar versions of Amgen's AMGN Prolia, Regeneron's Eylea and J&J's Simponi are under review in the United States, and those of Amgen's Xgeva, Simponi and Prolia are under review in the EU. A biosimilar of Novartis' Xolair is in late-stage development. Teva's U.S. generics/biosimilars business looks stable now, much more than it has been in years. Its U.S. generics/biosimilars business rose 15% in the United States in 2024, driven by new product launches. Teva expects continued growth in its U.S. generics business in 2025, driven by complex product launches like Victoza, Forteo and others, as well as upcoming launches of Symbicort, Saxenda and biosimilars Simlandi and Selarsdi. The company aims to double its global biosimilars sales by 2027 from approximately $400 million in 2024, supported by five product launches expected by then. Teva stock has lost 25% so far this year compared with the industry's 9.5% decline. Image Source: Zacks Investment Research The stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company shares currently trade at 6.30 on a forward 12-month basis, lower than 10.17 for the industry. However, the stock is trading above its 5-year mean of 4.11. Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has declined from $2.56 per share to $2.51 for 2025 but risen from $2.66 to $2.72 for 2026 over the past 60 days. Image Source: Zacks Investment Research Teva's revenues have suffered significantly since it lost exclusivity for key multiple sclerosis medicine, Copaxone, in 2015. The company also faces competitive pressure for some of its key branded drugs. It also has a high debt load and faces some price-fixing charges. The company may face a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers' Revlimid) in 2026, as well as headwinds in 2027 related to the IRA Medicare Part D negotiation for Austedo. However, its newer drugs, Austedo, Uzedy and Ajovy, and stable generics business are reviving top-line growth. With the nationwide settlement of the costly opioid litigations, new product launches, stability in the generics segment with contributions from biosimilars, and a robust pipeline of biosimilars and branded products, the path for Teva's long-term growth is becoming clearer. The company is saving costs and improving margins through the optimization of operations for efficiency while also lowering thedebt on its balance sheet. Teva expects an adjusted operating margin of 30% by 2027 through cost savings and the continued growth of its branded drugs. In the past few months, Fitch, Moody's and S&P have upgraded their respective credit outlook for Teva, reflecting improved growth prospects. TEVA'simproving branded and biosimilar pipeline and the prospect of growth in sales and profits are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Globe and Mail
11-07-2025
- Business
- Globe and Mail
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited 's TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics, with many more in the pipeline. The company's newer branded drugs, such as Austedo, Uzedy and Ajovy, are experiencing strong sales growth. Teva has implemented cost-cutting measures to improve its operating profits while reducing debt burden. All these factors have played a key role in the stock's price appreciation in the past three months. Let's discuss these factors in detail to understand how to play TEVA stock at present. TEVA's New Branded Drugs Driving Growth The company is seeing continued market share growth of its two newest branded drugs, Austedo and Ajovy. Though Teva is seeing slightly slower growth of Ajovy in the U.S. market, it expects sales to benefit from continued patient growth and launches in additional countries in Europe and international markets. For Austedo, Teva expects to achieve annual revenues of more than $2.5 billion by 2027. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects to launch Austedo in European markets in 2026. Uzedy (risperidone) extended-release injectable suspension, a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia in adults, was launched in May 2023 in the United States. In 2025, Uzedy sales are expected to be approximately $160 million. The company has also made decent progress with its branded pipeline, which includes olanzapine, a long-acting subcutaneous injectable (LAI) for treating schizophrenia and duvakitug, its anti-TL1A therapy for inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD). Teva has partnered with Sanofi SNY for duvakitug to maximize the value of the asset. Teva and Sanofi will equally share the development costs globally. Teva's partner, Sanofi, plans to advance duvakitug, into phase III trials for both UC and CD in the fourth quarter of 2025. The company expects to file a new drug application to seek approval for olanzapine in the second half. Teva anticipates generating more than $5 billion in revenues from its branded products by 2030. TEVA's Strengthening Generics and Biosimilar Pipeline Over the past few quarters, Teva has successfully launched several biosimilars and other high-value complex generics, including Novo Nordisk's Victoza, Roche's cancer drugs Rituxan (Truxima) and Herceptin (Herzuma), AbbVie's Humira (Simlandi), J&J's JNJ Stelara (Selarsdi), Novartis' Sandostatin LAR and AstraZeneca's Soliris (Epysqli). Teva has a decent pipeline of biosimilars, with some being developed in partnership with Alvotech, including high-value complex generics like Simlandi and Selarsdi. These are the first two biosimilars to be launched in the United States under the Teva and Alvotech strategic partnership, which includes five biosimilars. TEVA expects to launch seven (including Simlandi and Selarsdi) biosimilars in the United States and four in Europe between 2025 and 2027. Biosimilar versions of Amgen 's AMGN Prolia, Regeneron's Eylea and J&J's Simponi are under review in the United States, and those of Amgen's Xgeva, Simponi and Prolia are under review in the EU. A biosimilar of Novartis' Xolair is in late-stage development. Teva's U.S. generics/biosimilars business looks stable now, much more than it has been in years. Its U.S. generics/biosimilars business rose 15% in the United States in 2024, driven by new product launches. Teva expects continued growth in its U.S. generics business in 2025, driven by complex product launches like Victoza, Forteo and others, as well as upcoming launches of Symbicort, Saxenda and biosimilars Simlandi and Selarsdi. The company aims to double its global biosimilars sales by 2027 from approximately $400 million in 2024, supported by five product launches expected by then. TEVA's Price, Valuation & Estimate Discussion Teva stock has lost 25% so far this year compared with the industry 's 9.5% decline. TEVA Stock Underperforms Industry YTD The stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company shares currently trade at 6.30 on a forward 12-month basis, lower than 10.17 for the industry. However, the stock is trading above its 5-year mean of 4.11. TEVA Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has declined from $2.56 per share to $2.51 for 2025 but risen from $2.66 to $2.72 for 2026 over the past 60 days. TEVA's Estimate Movement Stay Invested in Teva's Stock Teva's revenues have suffered significantly since it lost exclusivity for key multiple sclerosis medicine, Copaxone, in 2015. The company also faces competitive pressure for some of its key branded drugs. It also has a high debt load and faces some price-fixing charges. The company may face a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers' Revlimid) in 2026, as well as headwinds in 2027 related to the IRA Medicare Part D negotiation for Austedo. However, its newer drugs, Austedo, Uzedy and Ajovy, and stable generics business are reviving top-line growth. With the nationwide settlement of the costly opioid litigations, new product launches, stability in the generics segment with contributions from biosimilars, and a robust pipeline of biosimilars and branded products, the path for Teva's long-term growth is becoming clearer. The company is saving costs and improving margins through the optimization of operations for efficiency while also lowering thedebt on its balance sheet. Teva expects an adjusted operating margin of 30% by 2027 through cost savings and the continued growth of its branded drugs. In the past few months, Fitch, Moody's and S&P have upgraded their respective credit outlook for Teva, reflecting improved growth prospects. TEVA'simproving branded and biosimilar pipeline and the prospect of growth in sales and profits are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
